Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

OTHER 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Neuroblastoma 2Pheochromocytoma 1Medulloblastoma 1Ependymoma 1

Interventions

3-Iodobenzylguanidine 13lutetium Lu 177 dotatate 5gallium Ga 68 dotatate 4Temozolomide 4Specimen Handling 4anlotinib 3Magnetic Resonance Spectroscopy 3Everolimus 3pegfilgrastim 2olaparib 2cabozantinib 2belzutifan 2Radiotherapy 2Phenoxybenzamine 2Nivolumab 2Granulocyte Colony-Stimulating Factor 2Fluorodeoxyglucose F18 2Biopsy 2Axitinib 23-fluorobenzylguanidine 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2vandetanib 1tipifarnib 1temsirolimus 1talazoparib 1spartalizumab 1pentetreotide 1penpulimab 1pembrolizumab 1pazopanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pheochromocytoma × Potassium Iodide × CNS × Clear all
NCT03649438 2024-12-11

131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma

University of Texas Southwestern Medical Center

No longer available
CNSEndocrine

Neuroblastoma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡